Literature DB >> 19620786

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.

Andrei Ivanov1, Stephen A Beers, Claire A Walshe, Jamie Honeychurch, Waleed Alduaij, Kerry L Cox, Kathleen N Potter, Stephen Murray, Claude H T Chan, Tetyana Klymenko, Jekaterina Erenpreisa, Martin J Glennie, Tim M Illidge, Mark S Cragg.   

Abstract

mAbs are becoming increasingly utilized in the treatment of lymphoid disorders. Although Fc-FcgammaR interactions are thought to account for much of their therapeutic effect, this does not explain why certain mAb specificities are more potent than others. An additional effector mechanism underlying the action of some mAbs is the direct induction of cell death. Previously, we demonstrated that certain CD20-specific mAbs (which we termed type II mAbs) evoke a nonapoptotic mode of cell death that appears to be linked with the induction of homotypic adhesion. Here, we reveal that peripheral relocalization of actin is critical for the adhesion and cell death induced by both the type II CD20-specific mAb tositumomab and an HLA-DR-specific mAb in both human lymphoma cell lines and primary chronic lymphocytic leukemia cells. The cell death elicited was rapid, nonapoptotic, nonautophagic, and dependent on the integrity of plasma membrane cholesterol and activation of the V-type ATPase. This cytoplasmic cell death involved lysosomes, which swelled and then dispersed their contents, including cathepsin B, into the cytoplasm and surrounding environment. The resulting loss of plasma membrane integrity occurred independently of caspases and was not controlled by Bcl-2. These experiments provide what we believe to be new insights into the mechanisms by which 2 clinically relevant mAbs elicit cell death and show that this homotypic adhesion-related cell death occurs through a lysosome-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620786      PMCID: PMC2719942          DOI: 10.1172/JCI37884

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

Review 1.  Clinical trials of antibody therapy.

Authors:  M J Glennie; P W Johnson
Journal:  Immunol Today       Date:  2000-08

2.  CD99 monoclonal antibody induce homotypic adhesion of Jurkat cells through protein tyrosine kinase and protein kinase C-dependent pathway.

Authors:  W Kasinrerk; N Tokrasinwit; S Moonsom; H Stockinger
Journal:  Immunol Lett       Date:  2000-01-10       Impact factor: 3.685

Review 3.  The axonal transport of mitochondria.

Authors:  Peter J Hollenbeck; William M Saxton
Journal:  J Cell Sci       Date:  2005-12-01       Impact factor: 5.285

Review 4.  Lysosomes and autophagy in cell death control.

Authors:  Guido Kroemer; Marja Jäättelä
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

5.  Dissociation of caspase-mediated events and programmed cell death induced via HLA-DR in follicular lymphoma.

Authors:  M Carmagnat; B Drénou; H Chahal; J M Lord; D Charron; J Estaquier; N A Mooney
Journal:  Oncogene       Date:  2006-03-23       Impact factor: 9.867

6.  Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.

Authors:  T Kataoka; N Shinohara; H Takayama; K Takaku; S Kondo; S Yonehara; K Nagai
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

7.  A retention mechanism for distribution of mitochondria during cell division in budding yeast.

Authors:  H C Yang; A Palazzo; T C Swayne; L A Pon
Journal:  Curr Biol       Date:  1999-10-07       Impact factor: 10.834

8.  Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine.

Authors:  Line Groth-Pedersen; Marie Stampe Ostenfeld; Maria Høyer-Hansen; Jesper Nylandsted; Marja Jäättelä
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

9.  An alternative, nonapoptotic form of programmed cell death.

Authors:  S Sperandio; I de Belle; D E Bredesen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

10.  Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis.

Authors:  Andrey Ivanov; Sergei Krysov; Mark S Cragg; Tim Illidge
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

View more
  66 in total

1.  Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.

Authors:  Kirstie L S Cleary; H T Claude Chan; Sonja James; Martin J Glennie; Mark S Cragg
Journal:  J Immunol       Date:  2017-04-12       Impact factor: 5.422

2.  Engaging the lysosomal compartment to combat B cell malignancies.

Authors:  Kirsten Grønbaek; Marja Jäättelä
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

3.  Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.

Authors:  Andrew T Vaughan; Claude H T Chan; Christian Klein; Martin J Glennie; Stephen A Beers; Mark S Cragg
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

Review 4.  Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Authors:  Ciara L Freeman; Laurie Sehn
Journal:  Curr Oncol Rep       Date:  2018-11-27       Impact factor: 5.075

Review 5.  Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.

Authors:  Fabrizio Marcucci; Matteo Bellone; Cristiano Rumio; Angelo Corti
Journal:  MAbs       Date:  2012-12-04       Impact factor: 5.857

6.  Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.

Authors:  Christian Klein; Alfred Lammens; Wolfgang Schäfer; Guy Georges; Manfred Schwaiger; Ekkehard Mössner; Karl-Peter Hopfner; Pablo Umaña; Gerhard Niederfellner
Journal:  MAbs       Date:  2012-12-04       Impact factor: 5.857

Review 7.  Anti-CD20 monoclonal antibodies: historical and future perspectives.

Authors:  Sean H Lim; Stephen A Beers; Ruth R French; Peter W M Johnson; Martin J Glennie; Mark S Cragg
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

8.  GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present.

Authors:  Delila J Kern; Britnie R James; Sue Blackwell; Christian Gassner; Christian Klein; George J Weiner
Journal:  Leuk Lymphoma       Date:  2013-04-16

Review 9.  Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective.

Authors:  Carolyn J Owen; Douglas A Stewart
Journal:  Ther Adv Hematol       Date:  2015-08

10.  Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

Authors:  Laurie H Sehn; Andre Goy; Fritz C Offner; Giovanni Martinelli; M Dolores Caballero; Ole Gadeberg; Tara Baetz; Andrew D Zelenetz; Gianluca Gaidano; Luis E Fayad; Rena Buckstein; Jonathan W Friedberg; Michael Crump; Branimir Jaksic; Pier Luigi Zinzani; Swaminathan Padmanabhan Iyer; Deniz Sahin; Akiko Chai; Günter Fingerle-Rowson; Oliver W Press
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.